Literature DB >> 30026450

[A Case of Drug-Induced Organizing Pneumonia Caused by Dasatinib].

Miyuki Sato1, Satoshi Watanabe, Nobumasa Aoki, Katsuaki Asakawa, Hiroshi Moriyama, Yasuyoshi Oshima, Toshiyuki Koya, Kiyoshi Okazuka, Toshiaki Kikuchi.   

Abstract

A 52-year-old man with chronic myelogenous leukemia (CML) received dasatinib after the failure of imatinib and nilotinib therapy. Two years after the initiation of dasatinib, he developed shortness of breath that gradually worsened. Chest X-ray and computed tomography scan showed pulmonary infiltrative shadows and bilateral pleural effusion. We performed a transbronchial lung biopsy and diagnosed organizing pneumonia caused by dasatinib treatment. Corticosteroid therapy was initiated after the discontinuation of dasatinib and all his symptoms were significantly improved. Because of the exacerbation of CML, the patient was treated with imatinib and then nilotinib; however, these drugs failed to decrease the leukemic cells. Re - administration of dasatinib in combination with corticosteroid therapy successfully controlled CML without recurrence of organizing pneumonia.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30026450

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib.

Authors:  Daisuke Takekoshi; Yuma Matsui; Takuya Akutsu; Ayako Nishioka; Ayu Kiritani; Keitaro Okuda; Junko Watanabe; Hanae Miyagawa; Hirohumi Utsumi; Mitsuo Hashimoto; Hiroshi Wakui; Shunsuke Minagawa; Hiromichi Hara; Takanori Numata; Yuki Noda; Rei Makishima; Masahiro Ikegami; Yoshinori Kawabata; Jun Araya; Kazuyoshi Kuwano
Journal:  Intern Med       Date:  2020-06-15       Impact factor: 1.271

Review 2.  Repurposing of Kinase Inhibitors for Treatment of COVID-19.

Authors:  Ellen Weisberg; Alexander Parent; Priscilla L Yang; Martin Sattler; Qingsong Liu; Qingwang Liu; Jinhua Wang; Chengcheng Meng; Sara J Buhrlage; Nathanael Gray; James D Griffin
Journal:  Pharm Res       Date:  2020-08-10       Impact factor: 4.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.